At the securities exchange, I worked on IPOs for biotech and technology companies. Later, a few co-founder attempts, including one company that reached unicorn valuation, pulled me toward a different question: how markets open, how products change behavior, and how new demand gets created.
Today I'm building an AI-enabled reproductive technology company, starting with surrogacy and maternal risk prediction across Thailand, the U.S., and South Korea.
My broader interests are ex vivo reproduction, fertility, and longevity. The thesis is simple: AI can remove friction from human reproduction and expand what people can do.
Friction is the wedge. When complex, expensive workflows become simple and natural, behavior changes. New demand shows up. New markets form.
Still an outsider to biology, I'm learning fast. This site is where I write that learning in public: ex vivo reproduction, Reprotech + AI, and the technologies and companies shaping the next generation of biotech startups.